Market Cap 489.14M
Revenue (ttm) 0.00
Net Income (ttm) -26.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 100,700
Avg Vol 304,798
Day's Range N/A - N/A
Shares Out 26.53M
Stochastic %K 10%
Beta -0.24
Analysts Strong Sell
Price Target $31.00

Company Profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 614 3150
Address:
1 Bridge Plaza, 2nd Floor, Suite 275, Fort Lee, United States
WallStWireAds
WallStWireAds Jul. 14 at 4:18 PM
$NVCT https://seekingalpha.com/pr/20582379-streetwatch-nuvectis-pharma-eyes-9_8-billion-oral-pnh-market-with-late-stage-nxp100-backed-by $TGTX $VRTX $JBIO $CRNX
0 · Reply
focafoca99
focafoca99 Jul. 14 at 3:11 PM
$NVCT spotlights its licensing deal for NXP100, a once-daily oral PNH therapy with 59.5% transfusion-free response vs eculizumab.
0 · Reply
newsfile_corp
newsfile_corp Jul. 14 at 2:41 PM
https://nfne.ws/304934 $NVCT #NVCT #PNH #WallStreetWire #Publishing #NASDAQ #Investing
0 · Reply
WallStWireAds
WallStWireAds Jul. 6 at 1:53 PM
$NVCT https://thefinanceherald.com/nuvectis-insiders-put-1-17-million-behind-the-stock-days-following-recent-haisco-deal-and-financing/ $URGN $AZN
0 · Reply
UNLV
UNLV Jul. 6 at 12:26 PM
$NVCT NXP100 a potential 1L treatment the biggest market potential. Coming 1b update not nearly as important nor as all encompassing as it once was NXP100, NXP200, NXP900 and $19 a share, LET’S GO. Potential to move like AI over a few years
0 · Reply
CosmicMiner
CosmicMiner Jul. 5 at 9:17 PM
Notable Insider Buys This Week: $BBD: $2.0M across 2 buys, Jul 1 $NVCT: $1.17M combined across 2 buys (2 insiders), Jun 30 $BOLD: $984K across 10 separate buys by one Chairman $CREX: $800K combined across 2 buys (CEO + CFO same day), Jun 30 $MDV: $163K across 4 buys by CEO (steady accumulation) "A lot of great opportunities if you know where to look. The battle map has been shared in the community! Are you going to miss out again?"
0 · Reply
buyandsold
buyandsold Jul. 4 at 2:39 PM
$NVCT It will all depend upon the toxicity profile. If you knock out src completely you would bet on major side effects.
1 · Reply
Merlintrader
Merlintrader Jul. 4 at 8:17 AM
$HDSN $NVCT $PSBD $CREX Insider trading this week: the 20 biggest buys and 20 biggest sells https://www.merlintrader.com/insider-trading-biggest-buys-sells-july-3-2026/
0 · Reply
UNLV
UNLV Jul. 2 at 1:39 PM
$NVCT Insider buys aren’t important these elevated prices. Supporting 100M offering during price pullback VERY IMPORTANT insiders aren’t selling. Continue predicting all 7 cohorts, “5 mono therapies - 2 resistance therapies” going to phase 2. I believe in the drug and the bio marker approach
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jul. 1 at 7:45 PM
$NVCT CEO purchased 12,500 shares at $20.00 for a total of $250,000. BENTSUR RON now owns 3,688,424 shares. https://ceo-buys.com
0 · Reply
Latest News on NVCT
Nuvectis Pharma 5M share Spot Secondary priced at $20.00

2026-06-30T10:10:10.000Z - 14 days ago

Nuvectis Pharma 5M share Spot Secondary priced at $20.00


Nuvectis Pharma TBA Spot Secondary; price range $20.00-$22.00

2026-06-29T21:50:11.000Z - 15 days ago

Nuvectis Pharma TBA Spot Secondary; price range $20.00-$22.00


Nuvectis Pharma Transcript: Status update

Jun 22, 2026, 8:30 AM EDT - 22 days ago

Nuvectis Pharma Transcript: Status update


Nuvectis Pharma Press release: Status update

Jun 22, 2026, 8:30 AM EDT - 22 days ago

Nuvectis Pharma Press release: Status update


Nuvectis Pharma Transcript: AGM 2026

Jun 11, 2026, 10:00 AM EDT - 4 weeks ago

Nuvectis Pharma Transcript: AGM 2026


Nuvectis Pharma Slides: Corporate presentation

May 11, 2026, 7:00 AM EDT - 2 months ago

Nuvectis Pharma Slides: Corporate presentation


Nuvectis Pharma Earnings release: Q1 2026

May 5, 2026, 7:30 AM EDT - 2 months ago

Nuvectis Pharma Earnings release: Q1 2026


Nuvectis Pharma Quarterly report: Q1 2026

May 5, 2026, 7:30 AM EDT - 2 months ago

Nuvectis Pharma Quarterly report: Q1 2026


Nuvectis Pharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Nuvectis Pharma Proxy statement: Proxy filing


Nuvectis Pharma Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Nuvectis Pharma Proxy statement: Proxy filing


Nuvectis Pharma management to meet with Maxim

2026-03-19T19:35:17.000Z - 4 months ago

Nuvectis Pharma management to meet with Maxim


Nuvectis Pharma Slides: Corporate presentation

Mar 13, 2026, 7:00 AM EDT - 4 months ago

Nuvectis Pharma Slides: Corporate presentation


Nuvectis Pharma files $150M mixed securities shelf

2026-02-13T21:05:11.000Z - 5 months ago

Nuvectis Pharma files $150M mixed securities shelf


Nuvectis Pharma Registration statement: Registration Filing

Feb 13, 2026, 7:00 AM EST - 5 months ago

Nuvectis Pharma Registration statement: Registration Filing


Nuvectis Pharma Earnings release: Q4 2025

Feb 11, 2026, 7:00 AM EST - 5 months ago

Nuvectis Pharma Earnings release: Q4 2025


Nuvectis Pharma Annual report: Q4 2025

Feb 11, 2026, 7:00 AM EST - 5 months ago

Nuvectis Pharma Annual report: Q4 2025


Nuvectis Pharma Transcript: KOL Event

Dec 2, 2025, 8:00 AM EST - 8 months ago

Nuvectis Pharma Transcript: KOL Event


Nuvectis Pharma Slides: KOL Event

Dec 2, 2025, 8:00 AM EST - 8 months ago

Nuvectis Pharma Slides: KOL Event


Nuvectis Pharma Earnings release: Q3 2025

Nov 4, 2025, 4:00 PM EST - 9 months ago

Nuvectis Pharma Earnings release: Q3 2025


Nuvectis Pharma Quarterly report: Q3 2025

Nov 4, 2025, 4:00 PM EST - 9 months ago

Nuvectis Pharma Quarterly report: Q3 2025


Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)

2025-11-04T13:20:44.000Z - 9 months ago

Nuvectis Pharma reports Q3 EPS (44c), consensus (25c)


Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year

2025-11-04T12:36:25.000Z - 9 months ago

Nuvectis Pharma reports Q3 net loss $7.5M vs $4.2M last year


Nuvectis Pharma appoints Juan Sanchez to board of directors

2025-09-25T12:05:11.000Z - 10 months ago

Nuvectis Pharma appoints Juan Sanchez to board of directors


Nuvectis Pharma Slides: Corporate Presentation

Sep 5, 2025, 7:00 AM EDT - 11 months ago

Nuvectis Pharma Slides: Corporate Presentation


Nuvectis Pharma Transcript: Status Update

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Transcript: Status Update


Nuvectis Pharma Press release: Status Update

Aug 12, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Press release: Status Update


Nuvectis Pharma initiates NXP900 program

2025-08-11T21:10:25.000Z - 1 year ago

Nuvectis Pharma initiates NXP900 program


Nuvectis Pharma Quarterly report: Q2 2025

Aug 5, 2025, 9:00 AM EDT - 1 year ago

Nuvectis Pharma Quarterly report: Q2 2025


Nuvectis Pharma Earnings release: Q2 2025

Aug 5, 2025, 9:00 AM EDT - 1 year ago

Nuvectis Pharma Earnings release: Q2 2025


Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year

2025-08-05T11:35:18.000Z - 1 year ago

Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year


Nuvectis Pharma Slides: Corporate Presentation

Jun 13, 2025, 11:00 AM EDT - 1 year ago

Nuvectis Pharma Slides: Corporate Presentation


Nuvectis Pharma Quarterly report: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Quarterly report: Q1 2025


Nuvectis Pharma Earnings release: Q1 2025

May 6, 2025, 8:30 AM EDT - 1 year ago

Nuvectis Pharma Earnings release: Q1 2025


Nuvectis Pharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Proxy statement: Proxy Filing


Nuvectis Pharma Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Nuvectis Pharma Proxy statement: Proxy Filing


Nuvectis Pharma Annual report: Q4 2024

Feb 25, 2025, 9:30 AM EST - 1 year ago

Nuvectis Pharma Annual report: Q4 2024


Nuvectis Pharma Earnings release: Q4 2024

Feb 25, 2025, 9:30 AM EST - 1 year ago

Nuvectis Pharma Earnings release: Q4 2024


Nuvectis Pharma Quarterly report: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma Quarterly report: Q3 2024


Nuvectis Pharma Earnings release: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Nuvectis Pharma Earnings release: Q3 2024


Nuvectis Pharma Quarterly report: Q2 2024

Aug 6, 2024, 8:45 AM EDT - 2 years ago

Nuvectis Pharma Quarterly report: Q2 2024


Nuvectis Pharma Earnings release: Q2 2024

Aug 6, 2024, 8:45 AM EDT - 2 years ago

Nuvectis Pharma Earnings release: Q2 2024


Nuvectis Pharma Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Quarterly report: Q1 2024


Nuvectis Pharma Earnings release: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Earnings release: Q1 2024


Nuvectis Pharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Proxy statement: Proxy Filing


Nuvectis Pharma Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma Proxy statement: Proxy Filing


Nuvectis Pharma Slides: Corporate Presentation

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Nuvectis Pharma Slides: Corporate Presentation


Nuvectis Pharma to Present at the 36th Annual Roth Conference

Mar 15, 2024, 8:00 AM EDT - 2 years ago

Nuvectis Pharma to Present at the 36th Annual Roth Conference


Nuvectis Pharma Earnings release: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Nuvectis Pharma Earnings release: Q4 2023


Nuvectis Pharma Annual report: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Nuvectis Pharma Annual report: Q4 2023


Nuvectis Pharma Quarterly report: Q3 2023

Nov 8, 2023, 7:00 AM EST - 2 years ago

Nuvectis Pharma Quarterly report: Q3 2023


Nuvectis Pharma Earnings release: Q3 2023

Nov 8, 2023, 7:00 AM EST - 2 years ago

Nuvectis Pharma Earnings release: Q3 2023


Nuvectis Pharma Transcript: Status Update

Sep 14, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Transcript: Status Update


Nuvectis Pharma Quarterly report: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Quarterly report: Q2 2023


Nuvectis Pharma Earnings release: Q2 2023

Aug 9, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Earnings release: Q2 2023


Nuvectis Pharma Announces FDA Clearance of NXP900 IND

May 15, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Announces FDA Clearance of NXP900 IND


Nuvectis Pharma Quarterly report: Q1 2023

May 10, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Quarterly report: Q1 2023


Nuvectis Pharma Earnings release: Q1 2023

May 10, 2023, 7:00 AM EDT - 3 years ago

Nuvectis Pharma Earnings release: Q1 2023


Nuvectis Pharma Proxy statement: Proxy Filing

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Proxy statement: Proxy Filing


Nuvectis Pharma Registration statement: Registration Filing

Mar 17, 2023, 8:00 AM EDT - 3 years ago

Nuvectis Pharma Registration statement: Registration Filing


WallStWireAds
WallStWireAds Jul. 14 at 4:18 PM
$NVCT https://seekingalpha.com/pr/20582379-streetwatch-nuvectis-pharma-eyes-9_8-billion-oral-pnh-market-with-late-stage-nxp100-backed-by $TGTX $VRTX $JBIO $CRNX
0 · Reply
focafoca99
focafoca99 Jul. 14 at 3:11 PM
$NVCT spotlights its licensing deal for NXP100, a once-daily oral PNH therapy with 59.5% transfusion-free response vs eculizumab.
0 · Reply
newsfile_corp
newsfile_corp Jul. 14 at 2:41 PM
https://nfne.ws/304934 $NVCT #NVCT #PNH #WallStreetWire #Publishing #NASDAQ #Investing
0 · Reply
WallStWireAds
WallStWireAds Jul. 6 at 1:53 PM
$NVCT https://thefinanceherald.com/nuvectis-insiders-put-1-17-million-behind-the-stock-days-following-recent-haisco-deal-and-financing/ $URGN $AZN
0 · Reply
UNLV
UNLV Jul. 6 at 12:26 PM
$NVCT NXP100 a potential 1L treatment the biggest market potential. Coming 1b update not nearly as important nor as all encompassing as it once was NXP100, NXP200, NXP900 and $19 a share, LET’S GO. Potential to move like AI over a few years
0 · Reply
CosmicMiner
CosmicMiner Jul. 5 at 9:17 PM
Notable Insider Buys This Week: $BBD: $2.0M across 2 buys, Jul 1 $NVCT: $1.17M combined across 2 buys (2 insiders), Jun 30 $BOLD: $984K across 10 separate buys by one Chairman $CREX: $800K combined across 2 buys (CEO + CFO same day), Jun 30 $MDV: $163K across 4 buys by CEO (steady accumulation) "A lot of great opportunities if you know where to look. The battle map has been shared in the community! Are you going to miss out again?"
0 · Reply
buyandsold
buyandsold Jul. 4 at 2:39 PM
$NVCT It will all depend upon the toxicity profile. If you knock out src completely you would bet on major side effects.
1 · Reply
Merlintrader
Merlintrader Jul. 4 at 8:17 AM
$HDSN $NVCT $PSBD $CREX Insider trading this week: the 20 biggest buys and 20 biggest sells https://www.merlintrader.com/insider-trading-biggest-buys-sells-july-3-2026/
0 · Reply
UNLV
UNLV Jul. 2 at 1:39 PM
$NVCT Insider buys aren’t important these elevated prices. Supporting 100M offering during price pullback VERY IMPORTANT insiders aren’t selling. Continue predicting all 7 cohorts, “5 mono therapies - 2 resistance therapies” going to phase 2. I believe in the drug and the bio marker approach
1 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jul. 1 at 7:45 PM
$NVCT CEO purchased 12,500 shares at $20.00 for a total of $250,000. BENTSUR RON now owns 3,688,424 shares. https://ceo-buys.com
0 · Reply
FilingTracker
FilingTracker Jul. 1 at 5:43 PM
$NVCT Another insider purchase: https://filingtracker.ai/filing/1875558/0001104659-26-079793
1 · Reply
FilingTracker
FilingTracker Jul. 1 at 5:41 PM
$NVCT Chairman/CEO purchased $250K worth of shares at $20/share: https://filingtracker.ai/filing/1875558/0001104659-26-079792
0 · Reply
UNLV
UNLV Jul. 1 at 7:40 AM
$NVCT entered June $9.75 and thought we were simply waiting 1b data 1/ Stock up 2x June 2/ License 2 drugs talked as best in class 3/ 100M offering around talk of dilution with stock doing a 2x June NEVER thought we’d be waiting 1b data around $18 and incredibly adding 2 new drugs
1 · Reply
UNLV
UNLV Jul. 1 at 7:22 AM
$NVCT 18.39 up 2x June. Licensed 2 drugs talked as best in class. 100M offering talk of dilution INCREDIBLE MONTH up 2x awaiting 1b data
0 · Reply
STACKD0E
STACKD0E Jul. 1 at 2:32 AM
$NVCT $CCCC $IMUX 🙃✨️
0 · Reply
History101
History101 Jun. 30 at 10:49 PM
$NVCT this should be at $20 soon, especially since no warrants in this public offering
1 · Reply
History101
History101 Jun. 30 at 8:22 PM
$NVCT me likey!!
0 · Reply
UNLV
UNLV Jun. 30 at 8:03 PM
$NVCT successful dilution if closing happens $20 on July 01. Huge success if we’re going into 1b update at significantly higher prices than stock traded ALL of last year CEO said he didn’t think anyone would complain around offering
1 · Reply
History101
History101 Jun. 30 at 7:54 PM
$NVCT 835 watching 6/30/2026
0 · Reply
History101
History101 Jun. 30 at 7:53 PM
$NVCT added, $18.49
0 · Reply
johnnygogogo
johnnygogogo Jun. 30 at 6:08 PM
$NVCT was just a couple of days off but hopefully I saved some of you from chasing in the short term. NP but watching / considering
0 · Reply
prismmarketview
prismmarketview Jun. 30 at 4:21 PM
PRISM Mid-Day Movers: Global Health and Crypto Mining are Today’s Leaders. Sangamo Therapeutics, Inc. (OTCQB: $SGMO) is ripping higher today, with the stock up about 48% to 0.074 from a prior close of 0.05. BTC Digital Ltd. (NASDAQ: $BTCT.X )is trading in a volatile range today, up roughly 40% with shares recently changing hands around the upper‑$0.60S after opening at $0.74 and moving between roughly $0.61 and $0.76 on very heavy volume of about 22 million shares. Other Notable Movers: Allurion ( $ALUR ) up 29% Surf Air Mobility ( $SRFM ) up 24% Nuvectis Pharma ( $NVCT ) down -35%
1 · Reply